#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

News

symptomatická léčba

Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM

19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)

Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy of symptomatic treatment with mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), with the longest follow-up period nearly 2.5 years. For clinical practice, the long-term reduction of left ventricular outflow tract (LVOT) obstruction and good tolerability of the treatment are particularly favorable.

farmakoterapie

Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction

Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to current…
19. 2. 2024 Source: Hypertrophic Cardiomyopathy (HCM)
starší muž aktivita

How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?

Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
15. 2. 2024 Source: Myelodysplastic Syndrome (MDS)
3D tisk

Planning Surgery Using 3D Printing in Practice – Case Study

In October 2023, an article by neurosurgeons from Leipzig University was published in the journal …
25. 1. 2024 Source: medScope.pro
trombocyty

Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?

Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the…
24. 1. 2024 Source: Immune Thrombocytopenia
klinickastudie

ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia

The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
24. 1. 2024 Source: Immune Thrombocytopenia
léčba leukemie_lékař a pacient

Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy

The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs…
24. 1. 2024 Source: Acute Myeloid Leukemia
docSova

Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment

Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is…
18. 1. 2024 Source: Deficiency of Alpha-1-Antitrypsin
kost_

Anabolic Antiosteoporotic Treatment as a First Step in Patients with Very High Fracture Risk

According to the 2022 opinion of the ESCEO (European Society for Clinical and Economic Aspects of…
18. 1. 2024 Source: Osteoporosis – Trends in Sequential Therapy
srdce

Cardio-renal-metabolic syndrome in context

The increase in the incidence of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and...
16. 1. 2024 Source: Heart Failure
1 13 14 15 16 17 161
Filter by speciality
Remove filters

Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#